Through sessions and Community Hubs, attendees of ACR Convergence 2021 have multiple opportunities to connect with other rheumatology professionals. Here are some helpful tips from panelists.
The ACR’s advocacy efforts over the past year have helped put critical prior authorization and step therapy legislation in front of Congress. Learn more at ACR Convergence 2021.
The MIPS Value Pathways will streamline federal reporting to better incentivize quality improvement. Start preparing for MVP with this session at ACR Convergence 2021.
Ghalandari et al. sought to validate the guidance outlined by EULAR for the use of anti-rheumatic drugs during pregnancy, finding that following its guidance for tumor necrosis factor inhibitors led to no or low concentrations of these agents in cord blood.
Initial 24-week data from a study of patients with psoriatic arthritis (PsA) show that treatment with guselkumab improved symptoms and resulted in a higher ACR20 response than placebo in patients who could not tolerate, or did not respond to, treatment with a tumor necrosis factor inhibitor (TNFi).
Weighing treatment options and adjusting them to meet the needs of patients with JIA is a complicated process. Experts discussed factors influencing treatment options, optimizing treatment doses and possibilities for treatment withdrawal for these patients.